iShares MSCI Germany (DAX) vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Germany (DAX) trades at $41.22, while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: iShares MSCI Germany (DAX) is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWG | INO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $2.87 |
52-Week Low | $38.08 | $1.05 |
Market Cap | — | $96.26M |
Enterprise Value | — | $67.27M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Trailing returns across standard periods
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →